Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy.

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• T cell-mediated immunotherapy shows promise for treating malignancies.
• Ex vivo expansion of tumor-reactive T cells is challenging due to low precursor frequency, leading to T cell exhaustion and loss of function.

Purpose of the Study:

• To develop an efficient method for expanding tumor-reactive T cells with preserved functionality.
• To establish a robust and reproducible protocol for generating T cells for immunotherapy.

Main Methods:

• Utilized highly purified naïve CD8+ T cells.
• Employed a single stimulation with peptide-pulsed, IFNγ/LPS-matured dendritic cells.
• Applied sequential cytokines: IL-21, IL-7, and IL-15 for T cell expansion.

Main Results:

• Achieved extensive expansion of antigen-specific T cells after a single stimulation.
• Expanded T cells demonstrated tumor reactivity and multifunctionality.
• Retained a central-memory-like phenotype (CD62L+, CCR7+, CD28+) in short-term expanded T cells.
• Demonstrated reproducibility across healthy donors and cancer patients.

Conclusions:

• Short-term expansion of tumor-antigen-primed T cells is feasible and effective.
• This method generates multifunctional T cells with a desirable memory phenotype.
• These T cells represent a promising platform for targeting various malignancies in immunotherapy.